Copy to clipboard 
DePuy Synthes reported 2Q26 orthopedic sales of $2.4 billion, up 4.9% compared to the second quarter of 2025. For the first half of the year, the company generated $4.8 billion in orthopedic sales, up 5.6%.
Growth in the second quarter was largely attributable to better commercial execution and new products like VOLT in trauma, ATTUNE and VELYS in knees and EMPHASYS in hips. DePuy Synthes’ Spine, Sports & Other segment faced headwinds from competitive pressure and inventory dynamics.
Johnson & Johnson continues to evaluate all separation options for DePuy Synthes while making progress on the planned spin-off in mid-2027.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q26 | 2Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $989.9 | $940.3 | $49.7 | 5.3% |
| Knees | $410.2 | $389.1 | $21.1 | 5.4% |
| Hips | $440.9 | $420.2 | $20.7 | 4.9% |
| Extremities | $138.8 | $130.9 | $7.9 | 6% |
| Spine | $233.1 | $240.3 | ($7.2) | (3%) |
| Trauma | $733.0 | $684.2 | $48.9 | 7.1% |
| Sports Medicine | $192.4 | $183.6 | $8.8 | 4.8% |
| Orthobiologics | $82.9 | $80.7 | $2.2 | 2.7% |
| Enabling Technology | $19.2 | $18.2 | $1.1 | 5.9% |
| Other | $167.5 | $157.9 | $9.6 | 6% |
| Total | $2,418.1 | $2,305.1 | $113.0 | 4.9% |
| 1H26 | 1H25 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,977.9 | $1,859.6 | $118.2 | 6.4% |
| Knees | $830.4 | $778.6 | $51.8 | 6.7% |
| Hips | $876.8 | $829.4 | $47.4 | 5.7% |
| Extremities | $270.6 | $251.6 | $19.0 | 7.6% |
| Spine | $446.0 | $457.5 | ($11.6) | (2.5%) |
| Trauma | $1,470.3 | $1,369.4 | $100.9 | 7.4% |
| Sports Medicine | $366.0 | $347.9 | $18.0 | 5.2% |
| Orthobiologics | $166.2 | $157.8 | $8.3 | 5.3% |
| Enabling Technology | $37.3 | $34.3 | $3.0 | 8.8% |
| Other | $337.8 | $319.6 | $18.2 | 5.7% |
| Total | $4,801.4 | $4,546.3 | $255.2 | 5.6% |
Orthopedic Sales by Geography
| Region | 2Q26 | 2Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,469.5 | $1,420.1 | $49.4 | 3.5% |
| OUS | $948.5 | $885.0 | $63.6 | 7.2% |
| EMEA | $458.6 | $429.2 | $29.4 | 6.9% |
| APAC | $317.8 | $292.0 | $25.7 | 8.8% |
| ROW | $172.2 | $163.7 | $8.4 | 5.2% |
| Total | $2,418.1 | $2,305.1 | $113.0 | 4.9% |
| Region | 1H26 | 1H25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,905.2 | $2,804.3 | $100.9 | 3.6% |
| OUS | $1,896.2 | $1,742.0 | $154.2 | 8.9% |
| EMEA | $913.5 | $840.6 | $72.9 | 8.7% |
| APAC | $640.0 | $587.7 | $52.3 | 8.9% |
| ROW | $342.7 | $313.7 | $29.0 | 9.3% |
| Total | $4,801.4 | $4,546.3 | $255.2 | 5.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $25,310.0 | |
| Cost of Sales | $8,051.0 | 31.8% |
| Selling and Admin | $6,432.0 | 25.4% |
| R & D | $3,653.0 | 14.4% |
| Other | $1,640.0 | 6.5% |
| Net Earnings | $5,534.0 | 21.9% |
DePuy Synthes reported 2Q26 orthopedic sales of $2.4 billion, up 4.9% compared to the second quarter of 2025. For the first half of the year, the company generated $4.8 billion in orthopedic sales, up 5.6%.
Growth in the second quarter was largely attributable to better commercial execution and new products like VOLT in trauma, ATTUNE and...
DePuy Synthes reported 2Q26 orthopedic sales of $2.4 billion, up 4.9% compared to the second quarter of 2025. For the first half of the year, the company generated $4.8 billion in orthopedic sales, up 5.6%.
Growth in the second quarter was largely attributable to better commercial execution and new products like VOLT in trauma, ATTUNE and VELYS in knees and EMPHASYS in hips. DePuy Synthes’ Spine, Sports & Other segment faced headwinds from competitive pressure and inventory dynamics.
Johnson & Johnson continues to evaluate all separation options for DePuy Synthes while making progress on the planned spin-off in mid-2027.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q26 | 2Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $989.9 | $940.3 | $49.7 | 5.3% |
| Knees | $410.2 | $389.1 | $21.1 | 5.4% |
| Hips | $440.9 | $420.2 | $20.7 | 4.9% |
| Extremities | $138.8 | $130.9 | $7.9 | 6% |
| Spine | $233.1 | $240.3 | ($7.2) | (3%) |
| Trauma | $733.0 | $684.2 | $48.9 | 7.1% |
| Sports Medicine | $192.4 | $183.6 | $8.8 | 4.8% |
| Orthobiologics | $82.9 | $80.7 | $2.2 | 2.7% |
| Enabling Technology | $19.2 | $18.2 | $1.1 | 5.9% |
| Other | $167.5 | $157.9 | $9.6 | 6% |
| Total | $2,418.1 | $2,305.1 | $113.0 | 4.9% |
| 1H26 | 1H25 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,977.9 | $1,859.6 | $118.2 | 6.4% |
| Knees | $830.4 | $778.6 | $51.8 | 6.7% |
| Hips | $876.8 | $829.4 | $47.4 | 5.7% |
| Extremities | $270.6 | $251.6 | $19.0 | 7.6% |
| Spine | $446.0 | $457.5 | ($11.6) | (2.5%) |
| Trauma | $1,470.3 | $1,369.4 | $100.9 | 7.4% |
| Sports Medicine | $366.0 | $347.9 | $18.0 | 5.2% |
| Orthobiologics | $166.2 | $157.8 | $8.3 | 5.3% |
| Enabling Technology | $37.3 | $34.3 | $3.0 | 8.8% |
| Other | $337.8 | $319.6 | $18.2 | 5.7% |
| Total | $4,801.4 | $4,546.3 | $255.2 | 5.6% |
Orthopedic Sales by Geography
| Region | 2Q26 | 2Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,469.5 | $1,420.1 | $49.4 | 3.5% |
| OUS | $948.5 | $885.0 | $63.6 | 7.2% |
| EMEA | $458.6 | $429.2 | $29.4 | 6.9% |
| APAC | $317.8 | $292.0 | $25.7 | 8.8% |
| ROW | $172.2 | $163.7 | $8.4 | 5.2% |
| Total | $2,418.1 | $2,305.1 | $113.0 | 4.9% |
| Region | 1H26 | 1H25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,905.2 | $2,804.3 | $100.9 | 3.6% |
| OUS | $1,896.2 | $1,742.0 | $154.2 | 8.9% |
| EMEA | $913.5 | $840.6 | $72.9 | 8.7% |
| APAC | $640.0 | $587.7 | $52.3 | 8.9% |
| ROW | $342.7 | $313.7 | $29.0 | 9.3% |
| Total | $4,801.4 | $4,546.3 | $255.2 | 5.6% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $25,310.0 | |
| Cost of Sales | $8,051.0 | 31.8% |
| Selling and Admin | $6,432.0 | 25.4% |
| R & D | $3,653.0 | 14.4% |
| Other | $1,640.0 | 6.5% |
| Net Earnings | $5,534.0 | 21.9% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
